ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: yosarian_2 who wrote (4465)	1/19/2017 11:51:07 AM
From: GregorioAllegri	of 4474

AML: I am certainly not as well informed as your friend's oncology doc... and maybe not as well informed as you... Try this: www.amlglobalportal.com Look through clinicaltrials.gov searching "Acute myeloid leukemia" Make sure she gets a mutational profile of her AML. Like NSCLC, it is actually a complex of several diseases with varying genetic causes. If lucky, there may be a targeted therapy trial for her to join or use off-label (e.g. ponatinib vs. certain mutant forms of FLT3.) If there are no targeted therapies, you might consider PD-1 checkpoint inhibitors (OPDIVO, KEYTRUDA) ncbi.nlm.nih.gov PD-1 inhibitors might be a better choice than targeted therapies if the disease is quite advanced and they tend to work, when they do, against almost all mutational types. It amazes me how big pharma keeps trying with chemo drugs, but that is only my opinion. Their effectiveness versus this disease appears, after a very superficial investigation, to be limited. Take with a grain of salt. I am a computational chemist, not an oncology doc. ga

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next